Proc. R. Soc. Med. Volume 60 July 1967 14 significant showing that commercial preparations can be satisfactorily given in divided doses on three successive days. The dosage schedule now used is given in Table 1. Ampoules of the commercial preparation Pergonal each contain 75 i.u. FSH, and up to 21 ampoules will readily dissolve in a total of 2 ml solvent. If another 1 ml solvent is then used to wash out each ampoule in succession and the combined 3 ml injected the total loss of FSH is not greater than 5 %. We believe that this is the safest, simplest and most economical method of treatment with human gonadotrophins.
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(1) It must be definitely established by a history of longstanding amenorrhoea, or basal temperature records, or endometrial biopsy within ten days of uterine bleeding that the patient is not ovulating. Clomiphene induces ovulation; it does not 'improve' ovulation.
(2) Urinary estimation of gonadotrophin must indicate that this pituitary hormone is present. Clomiphene does not invent the hormone or supplement it, it merely releases it in the correct ratio to induce ovulation.
(3) Seminal analysis must indicate that the patient's husband is fecund. (4) If there is any doubt about tubal patency a salpingogram or insufflation should be carried out.
Women with high titres of gonadotrophins are suffering from primary ovarian deficiency, not from inability to release adequate quantities of gonadotrophin to induce ovulation. Clomiphene treatment is therefore disappointing in these cases.
Women with low, or no, urinary gonadotrophins will not release adequate quantities to induce ovulation and would be better treated with human pituitary gonadotrophin.
There is a tendency for clomiphene-induced ovulatory cycles to have short post-ovulatory phases and inadequate luteal influence. In such cases injections of chorionic gonadotrophin during the post-ovulatory phase have improved the chances of a successful pregnancy where conception has followed clomiphene treatment.
We have not encountered any serious sideeffects or complications.
Results: Of 190 patients with ovulatory failure treated with clomiphene, 132 (69%) responded; 101 cases of anovulatory infertility were treated and of these 25 conceived immediately and 11 subsequently, a total of 36 %.
The outcome of the 36 pregnancies was as follows: there were 15 single births and 3 sets of twins; there was one neonatal death (at 27 weeks) and there have been 7 miscarriages; the remaining 10 patients have not yet been delivered.
